This study is for subjects who have been diagnosed with acute leukemia or myelodysplastic syndrome (MDS) and are a candidate for allogeneic hematopoietic stem cell transplant (HSCT). The study is being done to learn if adding defibrotide to the standard medicines for prevention of acute Graft-versus-Host Disease (aGvHD), which is called immunoprophylaxis, will help to prevent aGvHD better than using the usual immunoprophylaxis medicines alone. The investigational drug in this study is called Defibrotide. The duration of participation for each patient is approximately 6 months.
This study is for patient that have been diagnosed with suspected lower respiratory tract infection. The purpose of this study is to evaluate a new test that may be able to find more lung infections than current tests can. This new test is called next-generation sequencing and looks in respiratory secretions for bacteria, viruses, fungi, and other organisms that may cause infection. We hope to learn more about the usefulness of this new test in identifying infections.
This study is for subjects who have been diagnosed with a type of lymph gland disease called Hodgkin Lymphoma which has come back or has not gone away after treatment, including the best treatment known for these diseases. Researchers believe subjects will benefit from an allogeneic (from another human) stem cell transplant which has been offered as a form of treatment for this disease in many other patients. After transplant we will provide a type of medication that targets the CD30+ protein, a protein that is commonly expressed in Hodgkin Lymphoma. This medication is called Brentuximab Vedotin (or Brentuximab). Subjects will be offered treatment with lower doses of chemotherapy drugs, as compared to the higher doses of chemotherapy drugs historically used in transplants for other diseases. This is known as reduced intensity therapy.The main purpose of this study is to determine the safety and outcome of following reduced intensity conditioning and allogeneic stem cell transplantation in selected patients with Hodgkin Lymphoma (specifically CD30+ HL patients) with Brentuximab Vedotin. Subjects can expect to be in this study for 3 years.